Senator proposes Hatch-Waxman change to boost generic development

US Senator Orrin Hatch has proposed an amendment to the Hatch-Waxman Act to “restore the careful balance” the act struck to incentivise generic drug development.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AIPPI 2018: Eli Lilly talks IPRs and biosimilar litigation

26 September 2018 The inter partes review process has had a huge impact on biosimilar litigation, but it isn’t truly fulfilling its goal of being an alternative to district court litigation.

Big Pharma

Fed Circuit spurns bid to review Hatch-Waxman Act venue limits

27 January 2021 The US Court of Appeals for the Federal Circuit has dismissed an attempt by Valeant Pharmaceuticals to overturn a ruling that restricted where Hatch-Waxman Act patent lawsuits can be filed.

More on this story

Americas

AIPPI 2018: Eli Lilly talks IPRs and biosimilar litigation

26 September 2018 The inter partes review process has had a huge impact on biosimilar litigation, but it isn’t truly fulfilling its goal of being an alternative to district court litigation.

Big Pharma

Fed Circuit spurns bid to review Hatch-Waxman Act venue limits

More on this story

Americas

AIPPI 2018: Eli Lilly talks IPRs and biosimilar litigation

26 September 2018 The inter partes review process has had a huge impact on biosimilar litigation, but it isn’t truly fulfilling its goal of being an alternative to district court litigation.

Big Pharma

Fed Circuit spurns bid to review Hatch-Waxman Act venue limits